2023年6月8日

耶那南部,澳大利亚墨尔本,澳大利亚,2023年6月8日(全球通讯社)——Opthea有限公司(纳斯达克:选择;ASX:选择),临床阶段生物制药公司开发新的治疗方法治疗非常普遍和进步的视网膜疾病,高兴地宣布任命Anshul Thakral先生作为公司董事会的非执行董事。与此同时任命,迈克尔先生Sistenich辞去非执行董事,董事会服役超过7年。Opthea主席杰里米•莱文博士说“我们非常感谢迈克尔Opthea他的贡献。在2015年加入董事会,迈克尔一直Opthea价值因素的增长,公司从早期临床研究转换为双ASX-Nasdaq上市公司运行全球registrational湿性AMD的3期临床试验。我们致以诚挚的感谢和最美好的祝愿迈克尔和扩展热烈欢迎Anshul作为董事会的成员。“Anshul Thakral先生是首席执行官和董事会成员发射疗法,临床开发公司支持的基金管理的全球投资公司凯雷和其生命科学业务Abingworth。Opthea首席执行官和董事总经理梅根·鲍德温博士说“Opthea进入一个大型的、non-dilutive结构化融资与凯雷和Abingworth,与2022年8月发射疗法。Anshul加入董事会Opthea进一步构建我们的关系推出治疗团队,我们期待着与Anshul密切合作推进我们三期项目。”Thakral先生曾在制药和生物技术行业20多年,是一位有经验的行政、管理顾问和企业家。“我很荣幸加入Opthea董事会和与伟大的思想在科学和医疗保健工作,“Thakral先生说。 “I feel confident that together, we will continue to find solutions for patients and drive value for shareholders.” Mr. Thakral was previously Chief Commercial Officer and Executive Vice President of Peri and Post-Approval Services at PPD, and prior to that was Global Head of PPD Biotech. Before PPD, Mr. Thakral ran the global life sciences business unit at Gerson Lehrman Group (GLG) and worked at McKinsey & Company as an associate principal in the health care practice, where he provided strategic advice to global pharmaceutical and biotechnology companies on growth, research and development, business development and commercialization. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy, is an Operating Executive at Carlyle and is a Venture Partner at Abingworth. Mr. Thakral holds a Master’s degree in Biomedical Engineering from Johns Hopkins University and a Masters Business Administration (MBA) from the Wharton School at the University of Pennsylvania. About Opthea Limited Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Authorized for release to ASX by Megan Baldwin, CEO & Managing Director Company & Media Enquiries: